首页> 外文期刊>International Journal of Engineering Business Management >Buffer Size Design in Pharmaceutical Packaging Lines: An Analytical Methodology Proposal and Case Study:
【24h】

Buffer Size Design in Pharmaceutical Packaging Lines: An Analytical Methodology Proposal and Case Study:

机译:药品包装生产线的缓冲液大小设计:分析方法提案和案例研究:

获取原文
       

摘要

In recent years, governmental pressure on reducing the cost of drugs, together with the growth in the number of generic manufacturers, have given a considerable boost to competition in the pharmaceutical sector. Such relevant market change has highlighted the necessity of controlling and improving performance in order to reduce costs while maintaining high quality-levels, both enhancing working capital management and increasing overall equipment effectiveness (OEE) of production lines (activities that had previously been somewhat neglected in the pharmaceutical sector). In this paper, the paradigm of buffer design for availability (BDFA) - an approach developed to conciliate these apparently conflicting strategies to achieve performance improvement and cost reduction - is briefly recalled and discussed, being contextualized in the state-of-the-art of buffer design research. Its valuable practical applicability and effectiveness is then demonstrated by the means of a real case study application, and future developments are eventually presented.
机译:近年来,政府在降低药品成本方面的压力以及仿制药生产商数量的增加,极大地推动了制药行业的竞争。这种相关的市场变化突显了控制和改善性能的必要性,以降低成本并保持高质量水平,既增强了营运资金管理又提高了生产线的整体设备效率(OEE)(以前在某些活动中被忽略的活动)制药业)。在本文中,简要回顾和讨论了可用性缓冲设计(BDFA)的范式-一种调和这些表面上相互矛盾的策略以实现性能提高和成本降低的方法-在最新技术的背景下进行了介绍。缓冲区设计研究。然后通过一个实际案例研究应用程序证明了其宝贵的实用性和有效性,并最终介绍了未来的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号